×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HAE – haemonetics corporation (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HAE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/18
12:58 pm
hae
HAE or SYK: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Low
Report
HAE or SYK: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
12/6
10:57 am
hae
Are Investors Undervaluing Haemonetics (HAE) Right Now? [Yahoo! Finance]
Low
Report
Are Investors Undervaluing Haemonetics (HAE) Right Now? [Yahoo! Finance]
12/6
08:06 am
hae
Haemonetics Co. (NYSE: HAE) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $116.00 price target on the stock.
Low
Report
Haemonetics Co. (NYSE: HAE) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $116.00 price target on the stock.
12/4
11:28 am
hae
Wall Street Analysts See a 27.84% Upside in Haemonetics (HAE): Can the Stock Really Move This High? [Yahoo! Finance]
Low
Report
Wall Street Analysts See a 27.84% Upside in Haemonetics (HAE): Can the Stock Really Move This High? [Yahoo! Finance]
12/4
09:43 am
hae
Haemonetics Co. (NYSE: HAE) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $108.00 price target on the stock.
Low
Report
Haemonetics Co. (NYSE: HAE) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $108.00 price target on the stock.
12/3
12:52 pm
hae
Haemonetics Co. (NYSE: HAE) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $112.00 price target on the stock.
Low
Report
Haemonetics Co. (NYSE: HAE) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $112.00 price target on the stock.
12/3
01:21 am
hae
Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A [Yahoo! Finance]
Low
Report
Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A [Yahoo! Finance]
12/3
01:16 am
hae
Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A
Low
Report
Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/3
06:08 am
hae
Form 8-K HAEMONETICS CORP For: Dec 03
Medium
Report
Form 8-K HAEMONETICS CORP For: Dec 03
11/14
01:29 pm
hae
Form SC 13G HAEMONETICS CORP Filed by: T. Rowe Price Investment Management, Inc.
Low
Report
Form SC 13G HAEMONETICS CORP Filed by: T. Rowe Price Investment Management, Inc.
11/12
12:54 pm
hae
Form SC 13G/A HAEMONETICS CORP Filed by: Capital Research Global Investors
Low
Report
Form SC 13G/A HAEMONETICS CORP Filed by: Capital Research Global Investors
11/12
11:26 am
hae
Form 144 HAEMONETICS CORP Filed by: Lingamneni Anila
Low
Report
Form 144 HAEMONETICS CORP Filed by: Lingamneni Anila
11/8
10:42 am
hae
Form SC 13G/A HAEMONETICS CORP Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SC 13G/A HAEMONETICS CORP Filed by: WELLINGTON MANAGEMENT GROUP LLP
11/7
06:12 am
hae
Form 10-Q HAEMONETICS CORP For: Sep 28
Medium
Report
Form 10-Q HAEMONETICS CORP For: Sep 28
11/7
06:04 am
hae
Form 8-K HAEMONETICS CORP For: Nov 07
Medium
Report
Form 8-K HAEMONETICS CORP For: Nov 07
11/5
04:17 pm
hae
Form 4 HAEMONETICS CORP For: Nov 01 Filed by: Galvin Roy
Medium
Report
Form 4 HAEMONETICS CORP For: Nov 01 Filed by: Galvin Roy
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/6
Q1/2020 6/29/2019 EPS 0.810 ZacksConsensus 0.630 ActVsEst 0.180 - Beat
12.0%
2/4 Q3/2020 12/28/2019 EPS 0.940 ZacksConsensus 0.760 ActVsEst 0.180 - Beat 9.5%
4/2 Haemonetics Acquires enicor GmbH to Expand Advanced Viscoelastic Testing Portfolio 8.9%
11/1 Q2/2020 9/28/2019 EPS 0.870 ZacksConsensus 0.720 ActVsEst 0.150 - Beat 7.2%
2/5 Haemonetics Co. (NYSE: HAE) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $142.00 price target on the stock. 7.2%
5/13 Form 5 HAEMONETICS CORP For: Mar 30 Filed by: KROLL MARK W 5.8%
4/13 Form 4 HAEMONETICS CORP For: Apr 09 Filed by: KROLL MARK W 5.1%
4/17 Michael Coyle Joins Haemonetics Board of Directors 4.7%
5/7 Q4/2019 3/30/2019 EPS 0.610 ZacksConsensus 0.550 ActVsEst 0.060 - Beat 4.4%
8/12 Form 4 HAEMONETICS CORP For: Aug 09 Filed by: Goldstein Dan 3.2%
2/4 Q3/2020 12/28/2019 EPS 0.940 ZacksConsensus 0.760 ActVsEst 0.180 - Beat 9.5%
4/2 Haemonetics Acquires enicor GmbH to Expand Advanced Viscoelastic Testing Portfolio 8.9%
11/1 Q2/2020 9/28/2019 EPS 0.870 ZacksConsensus 0.720 ActVsEst 0.150 - Beat 7.2%
2/5 Haemonetics Co. (NYSE: HAE) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $142.00 price target on the stock. 7.2%
5/13 Form 5 HAEMONETICS CORP For: Mar 30 Filed by: KROLL MARK W 5.8%
4/13 Form 4 HAEMONETICS CORP For: Apr 09 Filed by: KROLL MARK W 5.1%
4/17 Michael Coyle Joins Haemonetics Board of Directors 4.7%
5/7 Q4/2019 3/30/2019 EPS 0.610 ZacksConsensus 0.550 ActVsEst 0.060 - Beat 4.4%
8/12 Form 4 HAEMONETICS CORP For: Aug 09 Filed by: Goldstein Dan 3.2%
TOP News Decliners
4/7
Haemonetics Co. (NYSE: HAE) had its price target lowered by analysts at Raymond James from $150.00 to $130.00. They now have an "outperform" rating on the stock.
-8.2%
11/2 Haemonetics (HAE) Q2 2020 Earnings Call Transcript [The Motley Fool] -6.5%
1/23 Haemonetics Co. (NYSE: HAE) had its price target lowered by analysts at Raymond James from $150.00 to $145.00. They now have an "outperform" rating on the stock. -4.8%
5/22 Form 10-K HAEMONETICS CORP For: Mar 30 -3.3%
3/30 Haemonetics Appoints Anila Lingamneni Executive Vice President, Chief Technology Officer -2.8%
5/11 Haemonetics Corporation (HAE) CEO Chris Simon on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -2.7%
5/24 Form 4 HAEMONETICS CORP For: May 22 Filed by: Simon, Christopher -2.6%
9/3 Form 4 HAEMONETICS CORP For: Aug 30 Filed by: Bolorforosh Said -2.1%
2/4 Form 10-Q HAEMONETICS CORP For: Dec 28 -2.0%
9/9 Form 4 HAEMONETICS CORP For: Sep 05 Filed by: Llorens Josep -1.7%
11/2 Haemonetics (HAE) Q2 2020 Earnings Call Transcript [The Motley Fool] -6.5%
1/23 Haemonetics Co. (NYSE: HAE) had its price target lowered by analysts at Raymond James from $150.00 to $145.00. They now have an "outperform" rating on the stock. -4.8%
5/22 Form 10-K HAEMONETICS CORP For: Mar 30 -3.3%
3/30 Haemonetics Appoints Anila Lingamneni Executive Vice President, Chief Technology Officer -2.8%
5/11 Haemonetics Corporation (HAE) CEO Chris Simon on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -2.7%
5/24 Form 4 HAEMONETICS CORP For: May 22 Filed by: Simon, Christopher -2.6%
9/3 Form 4 HAEMONETICS CORP For: Aug 30 Filed by: Bolorforosh Said -2.1%
2/4 Form 10-Q HAEMONETICS CORP For: Dec 28 -2.0%
9/9 Form 4 HAEMONETICS CORP For: Sep 05 Filed by: Llorens Josep -1.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: